Conférence

Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)

Réalisation : 1 décembre 2012 Mise en ligne : 1 décembre 2012
  • document 1 document 2 document 3
  • niveau 1 niveau 2 niveau 3
  • audio 1 audio 2 audio 3
Descriptif

Title : Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)Speaker: Patrick ROSSIGNOL, Nancy, FRAAbstract : RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication that occurs in renal patients. Nearly all CV prevention and heart failure trials excluded patients with moderate to severe CKD. Therefore, the general approach and recommendations for CV prevention in the general population may not be equally effective and completely safe in renal patients.- Renal failure is associated with increased vascular inflammation and oxidative stress linked to development of cardiovascular disease. Nrf-2 (NF-E2-related factor 2) is a regulator of anti-oxidant, anti-inflammatory and detoxification pathways. Intervention trials of the synthetic nrf2/nf?b modulator, bardoloxone methyl, in patients with advanced kidney disease associated with type 2 diabetes, demonstrated improvement of renal function (BEAM trial), suggesting that such agents may have therapeutic benefit in chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients with Stage 4 CKD and type 2 diabetes.- More specifically in chronic hemodialysis patients, results from the very few clinical trials undertaken thus far, including trials on lipid reduction, normalization of hematocrit, and increased dialysis dosage, have been unsuccessful.- New CV prevention opportunities are being investigated in specific trials in CKD and hemodialysis patients.The aim of this workshop is to discuss innovative designs and execution plans of CV prevention trials in CKD as well as the interpretation and implementation of the results of such trials and the approvability - regitrsbaility of potentially new CV prevention in CKD indications.Chairpersons: David GOLDSMITH, London, GBR - Luis RUILOPE, Madrid, ESPRéalisation, production : Canal U/3S et CERIMESKeyword : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, Baro-stimulation

Langue :
Anglais
Conditions d'utilisation
Droit commun de la propriété intellectuelle
Citer cette ressource:
Canal-U-Médecine. (2012, 1 décembre). Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST). [Vidéo]. Canal-U. https://www.canal-u.tv/60361. (Consultée le 27 janvier 2022)
Contacter

Dans la même collection

Avec les mêmes intervenants

  • 10ème Journée de la RECHERCHE HOSPITALO-UNIVERSITAIRE 2015- Les pôles en Recherche
    Conférence
    01:34:26
    10ème Journée de la RECHERCHE HOSPITALO-UNIVERSITAIRE 2015- Les pôles en Recherche
    Rossignol
    Patrick
    Koessler
    Laurent
    Parietti-Winkler
    Cécile
    Imbert
    Laëtitia
    Karcher
    Gilles
    Jonas
    Jacques
    Chabot-Lecoanet
    Anne-Claire
    Maigrat
    Charles-Henry
    Suty
    Christine
    Pizard
    Anne

    10e journée de la recherche hospitalo-universitaire  le 13 novembre 2015- CHRU de Nancy Titre : Les pôles en Recherche Auteur (s) : * Joao Ferreira + P.Rossignol * Julien Frère + C. Parietti

Sur le même thème